// App-Quantinova.ai

2163 : CPI-0610, a Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As Monotherapy in Advanced Myelofibrosis Patients Refractory/Intolerant to JAK Inhibitor: Update from Phase 2 MANIFEST Study

Researchers

Presenter

  • Moshe Talpaz

Principal Investigators

  • Srdan Verstovsek

  • Claire Harrison

  • Mark W. Drummond

  • Jean-Jacques Kiladjian

  • Alessandro Vannucchi

  • Marina Kremyanskaya

  • Gary J. Schiller

  • Andrea Patriarca

  • Gwendolyn Van Gorkom

  • Prithviraj Bose

  • Ronald Hoffman

  • Katarina Luptakova

  • Jessica Christo

  • Jing Wang

  • Jennifer A Mertz

  • Gozde Colak

  • James Shao

  • Suresh Bobba

  • Patrick Trojer

  • Adrian Senderowicz

  • John Mascarenhas

Medical Centers

  • Rogel Cancer Center, The University of Michigan, Ann Arbor, MI

  • Leukemia Service, Department of Medicine, Clinical Director, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Clinical Investigations Center, Saint-Louis hospital, Université de Paris, Paris, France

  • Hematology, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy

  • Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai / The Tisch Cancer Institute, New York, NY

  • David Geffen School of Medcn at UCLA, Los Angeles, CA

  • Azienda Ospedaliero Universitaria Maggiore della Carità di Novara SCDU Ematologia, Novara, Italy

  • University Hospital Maastricht, Maastricht, Netherlands

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Constellation Pharmaceuticals, Inc., Cambridge, MA

  • Constellation Pharmaceuticals, CAMBRIDGE, MA

Locations

  • United States

  • United Kingdom

  • France

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Thrombocytopenia

  • Myelofibrosis

  • Anemia

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Nucleoside diphosphate kinase A

  • Calreticulin

  • Janus kinase

  • Red Blood Cells

Drug/Treatment

  • Erythropoietin

  • Ruxolitinib phosphate

  • CPI-0610

Outcome

  • N/A

Study Design

  • Open Label

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved